Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 839 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: EGFR Clear all

Conditions: Squamous Cell Carcinoma
Interventions: Cisplatin, IMRT, Docetaxel, Cetuximab; Drug · Radiation
Lead sponsor: Christopher Wilke; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Non-Small Cell Lung Cancer
Interventions: ANS02; Drug
Lead sponsor: Avistone Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Non-Small Cell Lung Cancer, c-MET
Interventions: Telisotuzumab Adizutecan, Standard of Care, Osimertinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 16
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 13 more

Conditions: Non-small Cell Lung Cancer
Interventions: Sutetinib Maleate Capsule; Drug
Lead sponsor: Teligene US; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 8
States / cities: Glendale, California • Washington D.C., District of Columbia • Athens, Georgia + 5 more

Conditions: Cancer
Interventions: CUDC-101; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Detroit, Michigan • San Antonio, Texas

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: CS1-CAR T Therapy, Cyclophosphamide, Fludarabine, Leukapheresis; Procedure · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: DHES0815A; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more

Conditions: Lung Cancer
Interventions: Niraparib, Osimertinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: NSCLC, Breast Cancer
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 5
States / cities: Long Beach, California • Hattiesburg, Mississippi • New York, New York + 2 more

Conditions: Solid Tumor
Interventions: RMC-4630, Cobimetinib, Drug: Osimertinib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • Orange, California + 18 more

Conditions: Lung Cancer
Interventions: 18F-PEG6-IPQA, Positron emission tomography (PET); Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions: erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: blood draw; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma or Malignant Glioma
Interventions: AMG 596, AMG 404; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2
Interventions: Not listed
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Minneapolis, Minnesota + 5 more

Conditions: HER2+ Cancer
Interventions: AVX901; Biological
Lead sponsor: H. Kim Lyerly; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: erlotinib, RAD001; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Nashville, Tennessee

Conditions: Metastatic Colorectal Cancer
Interventions: Panitumumab, Cetuximab, Irinotecan, FOLFIRI Protocol, Bevacizumab; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Glioma, Malignant
Interventions: D2C7-IT, 2141-V11; Drug
Lead sponsor: Darell Bigner; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Metastatic Solid Tumor, Locally Advanced Solid Tumor
Interventions: Topical Tretinoin, Placebo; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: ART6043, Olaparib; Drug
Lead sponsor: Artios Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 4 more

Conditions: Breast Cancer
Interventions: ZN-c5; Drug
Lead sponsor: Zeno Alpha Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: Tucson, Arizona • New York, New York • Nashville, Tennessee + 2 more

Conditions: Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
Interventions: QRX-3; Drug
Lead sponsor: Ebima Clifford Okundaye; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Pasedena, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel; Drug
Lead sponsor: OSI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 19
States / cities: Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more

Search by objective public record fields.

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Study of 18F-Fluoro-PEG6-IPQA

Erlotinib in Treating Patients With Unresectable Liver Cancer and Liver Dysfunction

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma

ATHENA: Natural History of Disease Study in Alport Syndrome Patients

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

A Study of ZN-c5 in Participants With Breast Cancer

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2